Effects of supra-physiological changes in human ovarian hormone levels on maximum force production of the first dorsal interosseus muscle

被引:5
作者
Elliott, KJ
Cable, NT
Reilly, T
Sefton, V
Kingsland, C
Diver, M
机构
[1] Univ London Kings Coll, GKT Sch Biomed Sci, Appl Biomed Sci Res Grp, London SE1 1UL, England
[2] Liverpool John Moores Univ, Sport & Exercise Sci Res Inst, Liverpool L3 5UX, Merseyside, England
[3] Liverpool Womens Hosp, Reprod Med Unit, Liverpool, Merseyside, England
[4] Univ Liverpool, Dept Clin Chem, Liverpool L69 3BX, Merseyside, England
关键词
D O I
10.1113/expphysiol.2004.028258
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The purpose of this study was to investigate the effects of supra-physiological changes in ovarian hormone levels on maximum force production in two conditions, one physiological (pregnancy) and one pseudo-physiological (in vitro fertilization (IVF) treatment). Forty IVF patients were tested at four distinct stages of treatment and 35 women were tested during each trimester of pregnancy and following parturition. Maximum voluntary isometric force per unit cross-sectional area of the first dorsal interosseus muscle was measured. Plasma concentrations of total and bioavailable oestradiol and testosterone were measured, in addition to the total concentrations of progesterone and human chorionic gonadotropin. Despite significant changes in the concentrations of total progesterone, 17beta-oestradiol, bioavailable oestradiol and testosterone between phases, strength did not change significantly throughout IVF treatment (1.30 +/- 0.29, 1.16 +/- 0.38, 1.20 +/- 0.29 and 1.26 +/- 0.34 N mm(-2), respectively, in the 4 phases of IVF treatment). Force production was significantly higher during the second trimester of pregnancy than following childbirth (1.33 +/- 0.20 N mm(-2) at week 12 of pregnancy, 1.51 +/- 0.42 N mm(-2) at week 20, 1.15 +/- 0.26 N mm(-2) at week 36 and 0.94 +/- 0.31 N mm(-2) at week 6 postnatal) but was not significantly correlated with any of the hormones measured. These data suggest that extreme changes in the concentrations of reproductive hormones do not affect the maximum force-generating capacity of young women.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 25 条
[1]   Lack of variation in muscle strength with menstrual status in healthy women aged 45-54 years: Data from a national survey [J].
Bassey, EJ ;
Mockett, SP ;
Fentem, PH .
EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY AND OCCUPATIONAL PHYSIOLOGY, 1996, 73 (3-4) :382-386
[2]  
DAVIES DV, 1972, GRAYS ANATOMY DESCRI, P266
[3]   The influence of menstrual cycle phase on skeletal muscle contractile characteristics in humans [J].
de Jonge, XAKJ ;
Boot, CRL ;
Thom, JM ;
Ruell, PA ;
Thompson, MW .
JOURNAL OF PHYSIOLOGY-LONDON, 2001, 530 (01) :161-166
[4]   Continuously combined hormone replacement therapy and bone turnover: the influence of dydrogesterone dose, smoking and initial degree of bone turnover [J].
de Valk-de Roo, GW ;
Netelenbos, JC ;
Peters-Muller, IRA ;
Voetberg, GA ;
van de Weijer, PHM ;
Bouman, AA ;
Popp-Snijders, C ;
Kenemans, P .
MATURITAS, 1997, 28 (02) :153-162
[5]   Effect of menstrual cycle phase on the concentration of bioavailable 17-β oestradiol and testosterone and muscle strength [J].
Elliott, KJ ;
Cable, NT ;
Reilly, T ;
Diver, MJ .
CLINICAL SCIENCE, 2003, 105 (06) :663-669
[6]  
FOTHERBY K, 1984, BIOCH STEROID HORMON, P409
[7]   A CROSS-SECTIONAL STUDY OF MUSCLE STRENGTH AND MASS IN 45-YEAR-OLD TO 78-YR-OLD MEN AND WOMEN [J].
FRONTERA, WR ;
HUGHES, VA ;
LUTZ, KJ ;
EVANS, WJ .
JOURNAL OF APPLIED PHYSIOLOGY, 1991, 71 (02) :644-650
[8]   PSYCHIATRIC COMPLICATIONS OF PROGESTERONE AND ORAL-CONTRACEPTIVES [J].
GLICK, ID ;
BENNETT, SE .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1981, 1 (06) :350-367
[9]   Effects of acute changes in oestrogen on muscle function of the first dorsal interosseus muscle in humans [J].
Greeves, JP ;
Cable, NT ;
Luckas, MJM ;
Reilly, T ;
Biljan, MM .
JOURNAL OF PHYSIOLOGY-LONDON, 1997, 500 (01) :265-270
[10]   Changes in muscle strength in women following the menopause: a longitudinal assessment of the efficacy of hormone replacement therapy [J].
Greeves, JP ;
Cable, NT ;
Reilly, T ;
Kingsland, C .
CLINICAL SCIENCE, 1999, 97 (01) :79-84